KEVIN POELKER: Open Payments
NPI 1144202862 · CAPE CORAL, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,302 in 43 payments from 17 companies in 2025. Trend: 2023 $1,860 · 2024 $881 · 2025 $1,302
Food & beverage: $1,302
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $367 |
| Madrigal Pharmaceuticals | 1 | $148 |
| Neurocrine BioSciences, Inc. | 1 | $136 |
| Abbott Laboratories | 1 | $102 |
| Lilly USA, LLC | 5 | $96 |
| Inspire Medical Systems, Inc. | 1 | $81 |
| CorVista Health, Inc. | 1 | $64 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 2 | $46 |
| PFIZER INC. | 2 | $43 |
Products named: Wegovy, REZDIFFRA, INGREZZA, Ozempic, MITRACLIP, INSPIRE, CorVista System, Rybelsus.
Industry payments across FL — which companies pay providers there.
